Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...

Here’s the branding news we’re tracking this week. This week in branding news, Audi revealed a new logo, the hosiery brand ...

The rest of AbbVie’s product portfolio, including Venclexta, Botox Therapeutic, and Vraylar are no slouches either. The pharmaceutical company also possesses a pipeline of 90+ compounds or ...

AbbVie announced Monday that it is buying Aliada Therapeutics, along with its lead drug candidate ALIA-1758 — an experimental antibody being tested for treating Alzheimer’s disease ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill.

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer EvolveImmune's ...

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $ ...

09:34 EDT AbbVie (ABBV) sees FY24 adjusted gross margin 84% Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...